Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
209
datasets available to search
ShareScore release 0.9.0
Dataset results
209 results for “Intrahepatic cholangiocarcinoma”
Raw Data for the article: Liver Transplantation for Unresectable Intrahepatic Cholangiocarcinoma: The Role of Sequencing Genetic Profiling
<p>Intrahepatic cholangiocarcinoma (iCCA) is a rare and aggressive primary liver tumor, characterized by a range of different clinical manifestations and by increasing incidence and mortality rates even after curative treatment with radical resection. In recent years, growing attention has been devoted to this disease and some evidence supports liver transplantation (LT) as an appropriate treatment for intrahepatic cholangiocarcinoma; evolving work has also provided a framework for better understanding the genetic basis of this cancer. The aim of this study was to provide a clinical description of our series of patients complemented with Next-Generation Sequencing genomic profiling. From 1999 to 2021, 12 patients who underwent LT with either iCCA or a combined hepatocellular and cholangiocellular carcinoma (HCC-iCCA) were included in this study. Mutations were observed in gene activating signaling pathways known to be involved with iCCA tumorigenesis (KRAS/MAPK, P53, PI3K-Akt/mTOR, cAMP, WNT, epigenetic regulation and chromatin remodeling). Among several others, a strong association was observed between the Notch pathway and tumor size (point-biserial <em>rho<sub>pb</sub></em> = 0.93). Our results are suggestive of the benefit potentially derived from molecular analysis to improve our diagnostic capabilities and to devise new treatment protocols, and eventually ameliorate long-term survival of patients affected by iCCA or HCC-iCCA.</p>
Raw Data for the article: Liver transplantation for unresectable intrahepatic cholangiocarcinoma: an Italian experience
<p>Intrahepatic cholangiocarcinoma (iCCA) is an aggressive form of primary liver cancer treated exclusively with surgery.</p> <p>Its incidence in the western world is growing lately [<a href="https://link.springer.com/article/10.1007/s13304-021-01064-w#ref-CR1">1</a>] and the overall 5-year survival is poor due to late diagnosis, since patients rarely present a jaundice differently from patients affected by perihilar cholangiocarcinoma. Ideally liver resection and regional lymphadenectomy are the best treatments; however, these are unfortunately connotated by a 75% recurrence rate 5 years after surgery. Systemic chemotherapy offers a minimal response, as well as loco-regional therapy such as selective internal radiotherapy (SIRT), with a survival varying from 11 to 15 months between the two therapies</p>
Conventional, Functional and Radiomics Assessment for Intrahepatic Cholangiocarcinoma.
<p>I uploaded the images of the manuscript "Conventional, Functional and Radiomics Assessment for Intrahepatic Cholangiocarcinoma".</p>
Intrahepatic cholangiocarcinoma and its Differential Diagnosis at MRI: How Radiologist Should Assess MR features.
<p>We uploaded the figures of the manuscript Intrahepatic cholangiocarcinoma and its Differential Diagnosis at MRI: How Radiologist Should Assess MR features submitted on Radiologia Medica.</p> <p> </p> <p><strong>Figure Legend</strong>:</p> <p>Figure 1: mass-forming ICC; the lesion shows a targetoid appearance, with central fibrous stroma in T2-W sequence (A, arrow), DWI (B: b800s/mm<sup>2</sup>, arrow) and ADC map (C, arrow). During contrast study (arterial phase (D, arrow), portal (E, arrow), transitional (F, arrow), the lesion shows a progressive contrast enhancement.</p> <p>Figure 2: mass-forming ICC on left lobe, with diffuse metastases. The lesions show in T2-W sequences (A, B and C, arrows) targetoid appearance with central fibrosis in ICC and necrosis in metastases; TA is also present in DWI (D: b800 s/mm<sup>2</sup>, arrow) and ADC map (E, arrow). In arterial phase (F, arrow) the lesions show rim APHE with progressive contrast enhancement during portal phase (G, arrow).</p> <p>Figure 3: periductal infiltrating ICC; in T2-W sequence the lesion shows hypeintense SI (A, arrow); in DWI (B, arrow) and ADC map (C, arrow), biliary stent causes a dysomogeneous SI. During arterial (D, arrow) and portal phase (E, arrow) the lesion shows a progressive contrast enhancement.</p> <p>Figure 4: intraductal growing ICC. In T2-W sequence (A, arrow) the lesion shows hyperintense SI, with biliary dilatation and restricted signal in DWI (B, arrow) and ADC map (C, arrow) during arterial (D, arrow), portal (E, arrow) and late phase (F, arrow) the lesion shows a progressive contrast enhancement.</p> <p>Figure 5: mCRC patient. The lesions show targetoid appearance in T2-W sequence (A, arrow), DWI (B, arrow) and ADC map (C, arrow). In arterial phase (D, arrow) the lesions show rim APHE and hypointense SI in portal (E and F, arrows) phase. In F the arrow shows a pheripheral rim enhancement.</p> <p>Figure 6: Peribiliary metastases in pancreatic cancer patient. In T2-W the lesion shows hyperintense SI (A, arrow), with restricted diffusion (B, arrow) and iso-hypointense SI in ADC map (C, arrow). During arterial (D, arrow), portal (E, arrow) and transitional (F, arrow) phase the lesion shows a progressive contrast enhancement.</p> <p>Figure 7: HCC patient. In T2-W the lesion shows iso-hypeintense SI (A, arrow), with hypointense SI in T1-W (B: in phase; C: out phase, arrows). During arterial phase the lesion shows APHE (D, arrow), with washout appearance (E, arrow) and capsule appearance (F, arrow). The Diffusion is restricted (G: b500 s/mm<sup>2</sup>; H: b800 s/mm<sup>2</sup> and I: ADC map, arrows).</p> <p>Figure 8: cHCC-ICC patient. The lesion shows targetoid appearance in T2-W (A, arrow) and T1-w sequences (B: in phase and C: out of phase, arrows). During contrast study, the lesion shows progressive contrast enhancement (D: arterial phase; E: portal phase and F: equilibrium phase, arrows). In DWI sequences, the lesion shows targetoid appearance (G= b50 s/mm<sup>2</sup>; H: b800s/mm<sup>2</sup> and I: ADC map, arrows)</p> <p>Figure 9: hepatic hemangioma; in T2 (A, arrow) sequence the lesion shows hyperintense SI, with progressive contrast enhancement in arterial (B, arrow), portal (C, arrow) and equilibrium (D: coronal plane, arrow) phase.</p>
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
ClinicalTrials.gov study NCT04251715. IPD Sharing: Not stated. Countries: 1. Publications: 1.
SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
ClinicalTrials.gov study NCT02807181. IPD Sharing: NO. Countries: 8. Publications: 0.
Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC)
ClinicalTrials.gov study NCT01862315. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
ClinicalTrials.gov study NCT03230318. IPD Sharing: NO. Countries: 11. Publications: 1.
Two-cohort Study of Toripalimab(PD1)+Lenvatnib, or Gemox+Lenvatinib in Advanced Intrahepatic Cholangiocarcinoma
ClinicalTrials.gov study NCT04361331. IPD Sharing: NO. Countries: 1. Publications: 5.
Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma.
ClinicalTrials.gov study NCT07224737. IPD Sharing: NO. Countries: 1. Publications: 13.
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carc
ClinicalTrials.gov study NCT05286814. IPD Sharing: YES. Countries: 1. Publications: 1.
DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma
ClinicalTrials.gov study NCT06194695. IPD Sharing: UNDECIDED. Countries: 1. Publications: 1.
Microwave Ablation Versus Liver Resection for Intrahepatic Cholangiocarcinoma
ClinicalTrials.gov study NCT06462742. IPD Sharing: NO. Countries: 1. Publications: 0.
Recombinant Human Adenovirus Type 5 Plus HAIC of FOLFOX for Intrahepatic Cholangiocarcinoma
ClinicalTrials.gov study NCT05124002. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma
ClinicalTrials.gov study NCT02548195. IPD Sharing: Not stated. Countries: 1. Publications: 6.
HAIC Sequential TAE Combined With Tislelizumab and Surufatinib in Unresectable Intrahepatic Cholangiocarcinoma
ClinicalTrials.gov study NCT06239532. IPD Sharing: NO. Countries: 1. Publications: 1.
Detecting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma (LyMIC)
ClinicalTrials.gov study NCT06381648. IPD Sharing: UNDECIDED. Countries: 2. Publications: 22.
Cisplatin and Gemcitabine Chemotherapy and Lenvatinib for Patients With Unresectable Intrahepatic Cholangiocarcinoma
ClinicalTrials.gov study NCT04527679. IPD Sharing: NO. Countries: 1. Publications: 3.
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
ClinicalTrials.gov study NCT04669496. IPD Sharing: NO. Countries: 1. Publications: 5.
Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
ClinicalTrials.gov study NCT05010668. IPD Sharing: NO. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.